Amy Burroughs Sells 14,583 Shares of Terns Pharmaceuticals (NASDAQ:TERN) Stock

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CEO Amy Burroughs sold 14,583 shares of the company’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $46.71, for a total value of $681,171.93. Following the completion of the transaction, the chief executive officer directly owned 288,976 shares in the company, valued at approximately $13,498,068.96. The trade was a 4.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Terns Pharmaceuticals Price Performance

TERN traded up $0.40 on Tuesday, reaching $46.47. 2,345,435 shares of the stock were exchanged, compared to its average volume of 2,131,948. The company’s 50-day moving average price is $38.89 and its 200 day moving average price is $26.65. Terns Pharmaceuticals, Inc. has a fifty-two week low of $1.87 and a fifty-two week high of $48.26. The firm has a market capitalization of $4.82 billion, a PE ratio of -45.12 and a beta of -0.31.

Wall Street Analyst Weigh In

TERN has been the subject of a number of research reports. UBS Group raised Terns Pharmaceuticals to a “strong-buy” rating in a report on Thursday, December 4th. Leerink Partners initiated coverage on shares of Terns Pharmaceuticals in a research report on Monday, February 9th. They set an “outperform” rating and a $58.00 price target for the company. Oppenheimer lifted their price objective on shares of Terns Pharmaceuticals from $28.00 to $58.00 and gave the company an “outperform” rating in a research note on Tuesday, December 9th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $70.00 price objective on shares of Terns Pharmaceuticals in a report on Wednesday, December 10th. Finally, BMO Capital Markets increased their price objective on shares of Terns Pharmaceuticals from $35.00 to $54.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 9th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $58.11.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of TERN. Morgan Stanley grew its stake in shares of Terns Pharmaceuticals by 4.7% during the 4th quarter. Morgan Stanley now owns 7,945,608 shares of the company’s stock worth $321,003,000 after purchasing an additional 356,513 shares during the period. Commodore Capital LP acquired a new position in shares of Terns Pharmaceuticals in the 3rd quarter valued at $42,807,000. Adage Capital Partners GP L.L.C. boosted its holdings in Terns Pharmaceuticals by 40.9% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,550,000 shares of the company’s stock worth $224,220,000 after buying an additional 1,611,000 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Terns Pharmaceuticals by 21.1% during the fourth quarter. Vanguard Group Inc. now owns 5,523,948 shares of the company’s stock worth $223,167,000 after buying an additional 964,031 shares in the last quarter. Finally, Vestal Point Capital LP acquired a new stake in Terns Pharmaceuticals during the fourth quarter valued at $181,800,000. 98.26% of the stock is owned by institutional investors and hedge funds.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.